Relmada Therapeutics's market cap is currently $9.47M. The company's EPS TTM is $-2.869; its P/E ratio is ―; Relmada Therapeutics is scheduled to report earnings on March 25, 2025, and the estimated EPS forecast is $-0.71. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ -1.26K	$ -3.75K	$ 0.00
Operating Income	$ -103.70M	$ -161.25M	$ -125.70M	$ -60.84M	$ -15.11M
EBITDA	$ 4.91M	$ -157.04M	$ -125.75M	$ -59.45M	$ -15.10M
Net Income	$ -98.79M	$ -157.04M	$ -125.75M	$ -59.46M	$ -15.01M
Balance Sheet
Cash & Short-Term Investments	$ 96.32M	$ 148.32M	$ 211.91M	$ 117.09M	$ 116.44M
Total Assets	$ 97.55M	$ 152.91M	$ 223.33M	$ 118.19M	$ 117.14M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 110.25K
Net Debt	$ -4.09M	$ -5.40M	$ -44.44M	$ -2.50M	$ -36.17M
Total Liabilities	$ 12.19M	$ 12.47M	$ 15.06M	$ 12.60M	$ 1.46M
Stockholders' Equity	$ 85.36M	$ 140.44M	$ 208.26M	$ 105.58M	$ 115.68M
Cash Flow
Free Cash Flow	$ -51.66M	$ -103.80M	$ -91.87M	$ -27.81M	-
Operating Cash Flow	$ -51.66M	$ -103.80M	$ -91.87M	$ -27.81M	-
Investing Cash Flow	$ 50.45M	$ 19.73M	$ -54.12M	$ -34.45M	-
Financing Cash Flow	$ -98.46K	$ 45.02M	$ 187.94M	$ 28.47M	$ 126.11K

Currency in USD

Relmada Therapeutics Earnings and Revenue History

Income Statement >

Relmada Therapeutics Debt to Assets

Balance Sheet >

Relmada Therapeutics Cash Flow

Cash Flow >

Relmada Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing